O. P. Nechay
Research Subjects
O. P. Nechay has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Oleksandr A. Tovkai
Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ
10 shared publications - D. M. Kvitka
Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ
8 shared publications - Volodymyr O. Palamarchuk
Український науково-практичний центр ендокринної хірургії, трансплантацїї ендокринних органів і тканин Міністерства охорони здоров’я України, Київ
7 shared publications Н. І. Белемець
5 shared publications- Evgenia Globa
Ukrainian Scientific and Practical Center of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine
4 shared publications - N. I. Belemets
Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine
3 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 2,p. 5-15
Analysis of surgical care in children with thyroid cancer: a 10-year single-center experience
Objective — to evaluate the clinical course of thyroid cancer in children requiring surgical treatment, including age and sex distribution, and to analyze preoperative, intraoperative, and postoperative features, as well as the frequency of early and late complications, recurrence/persistence rates, their predictors, and subsequent management. Materials and methods. This retrospective cohort study included 456 children (≤18 years) who underwent thyroid surgery at the Center between 2013 and 2022. Based on clinical, laboratory, and histopathological findings, patients were divided into three groups: thyroid cancer (n=241), nodular goiter (n=151), and Graves’ disease (n=64). In patients with thyroid cancer, preoperative assessment included disease duration, age, sex distribution, thyroid function, and imaging results (thyroid ultrasound and fine-needle aspiration biopsy [FNAB] with cytological evaluation according to the Bethesda system). In 191 (79.2%) patients available for follow-up, postoperative thyroid function, early and late complications, recurrence/persistence of disease, time to occurrence, and further treatment were analyzed. Results. Among thyroid diseases requiring surgical intervention, thyroid cancer predominated (52.8%). The majority of patients were female (75%). The mean age of children with thyroid cancer was 14.2±2.8 years. Most patients were euthyroid (85.1%) and had a solitary thyroid nodule (69.4%) on ultrasound. The median duration of disease before surgery was 2.2 [1.0; 12.0] months. Total thyroidectomy with lymph node dissection was the most frequently performed procedure (89%). Histopathological examination revealed a predominance of papillary thyroid carcinoma (90.9%), with stage T1N0M0 in 34.3% of cases. The median follow-up period was 32.2 [16.0; 55.9] months. Late postoperative complications occurred in 2.9% (n=4) of patients and included persistent hypoparathyroidism and recurrent laryngeal nerve palsy, each observed in 1.45% of cases. The recurrence/persistence rate was 6.8%. Predictors included more advanced disease stage at diagnosis and high-risk papillary thyroid carcinoma, particularly the diffuse sclerosing variant. Management of recurrence/persistence included radioiodine (¹³¹I) therapy in all patients, repeat surgery (69.2%), or a combination of modalities. Conclusions. Thyroid cancer predominates among thyroid diseases requiring surgical treatment in children, with papillary carcinoma being the most common histological type. Surgical treatment is more frequently performed during puberty and in females. The rate of late postoperative complications (persistent hypoparathyroidism and recurrent laryngeal nerve palsy) is consistent with previously reported data. Children with thyroid nodules in Ukraine demonstrate a higher oncological risk, underscoring the need for careful diagnostic evaluation.
- 30 June 2026
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 2,p. 5-15
Open AccessAnalysis of surgical care in children with thyroid cancer: a 10-year single-center experience
Objective — to evaluate the clinical course of thyroid cancer in children requiring surgical treatment, including age and sex distribution, and to analyze preoperative, intraoperative, and postoperative features, as well as the frequency of early and late complications, recurrence/persistence rates, their predictors, and subsequent management. Materials and methods. This retrospective cohort study included 456 children (≤18 years) who underwent thyroid surgery at the Center between 2013 and 2022. Based on clinical, laboratory, and histopathological findings, patients were divided into three groups: thyroid cancer (n=241), nodular goiter (n=151), and Graves’ disease (n=64). In patients with thyroid cancer, preoperative assessment included disease duration, age, sex distribution, thyroid function, and imaging results (thyroid ultrasound and fine-needle aspiration biopsy [FNAB] with cytological evaluation according to the Bethesda system). In 191 (79.2%) patients available for follow-up, postoperative thyroid function, early and late complications, recurrence/persistence of disease, time to occurrence, and further treatment were analyzed. Results. Among thyroid diseases requiring surgical intervention, thyroid cancer predominated (52.8%). The majority of patients were female (75%). The mean age of children with thyroid cancer was 14.2±2.8 years. Most patients were euthyroid (85.1%) and had a solitary thyroid nodule (69.4%) on ultrasound. The median duration of disease before surgery was 2.2 [1.0; 12.0] months. Total thyroidectomy with lymph node dissection was the most frequently performed procedure (89%). Histopathological examination revealed a predominance of papillary thyroid carcinoma (90.9%), with stage T1N0M0 in 34.3% of cases. The median follow-up period was 32.2 [16.0; 55.9] months. Late postoperative complications occurred in 2.9% (n=4) of patients and included persistent hypoparathyroidism and recurrent laryngeal nerve palsy, each observed in 1.45% of cases. The recurrence/persistence rate was 6.8%. Predictors included more advanced disease stage at diagnosis and high-risk papillary thyroid carcinoma, particularly the diffuse sclerosing variant. Management of recurrence/persistence included radioiodine (¹³¹I) therapy in all patients, repeat surgery (69.2%), or a combination of modalities. Conclusions. Thyroid cancer predominates among thyroid diseases requiring surgical treatment in children, with papillary carcinoma being the most common histological type. Surgical treatment is more frequently performed during puberty and in females. The rate of late postoperative complications (persistent hypoparathyroidism and recurrent laryngeal nerve palsy) is consistent with previously reported data. Children with thyroid nodules in Ukraine demonstrate a higher oncological risk, underscoring the need for careful diagnostic evaluation.
- Open Access
- 30 September 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 29-34
Післяопераційно діагностовані карциноми щитоподібної залози при хворобі Грейвса у дітей
Хвороба Грейвса (ХГ) у дітей трапляється нечасто, уражаючи 1,5—6,5 осіб на 100 тис. населення зі збільшенням частоти в підлітковому віці. Захворюваність на рак щитоподібної залози (РЩЗ), який рідко спостерігається в педіатричній практиці, зростає. Поєднання ХГ і РЩЗ недостатньо висвітлено в літературі. Тому актуальним є вивчення перебігу та результатів хірургічного лікування при РЩЗ у дітей, прооперованих з приводу ХГ. Мета роботи — вивчити особливості перебігу карциноми щитоподібної залози, діагностованої після операції з приводу ХГ у дітей. Матеріали та методи. Проаналізовано 660 історій хвороби дітей (≤ 18 років), які перенесли операцію на щитоподібній залозі в 2013—2024 рр., із них 74 мали ХГ. У 6 (8,1%) дітей після операції діагностовано рак ЩЗ. Доопераційна діагностика передбачала дослідження функції щитоподібної залози, ультразвукове дослідження (УЗД) і тонкоголкову аспіраційну пункційну біопсію (ТАПБ) в окремих випадках, післяопераційне спостереження — УЗД і гормональний контроль кожні 6 міс. Результати. Більшість пацієнтів (82,4%) були підлітками (середній вік — близько 15 років). Серед пацієнтів переважали дівчата. Рак діагностований лише після операції, тобто не виявлений до операції за даними УЗД або ТАПБ. Усі 6 випадків раку були папілярними мікрокарциномами щитоподібної залози (< 10 мм, T1aN0М0). Лімфоїдна інфільтрація наявна в усіх випадках раку, навіть у навколишній тканині. Післяопераційні ускладнення мали минущий характер: у 20,0% — гіпопаратиреоз, у 9,1% — парез зворотного гортанного нерва. Тривале спостереження за дітьми з установленим раком щитоподібної залози на тлі ХГ не виявило рецидивів, у 3 із них — понад 5 років. Висновки. Рак щитоподібної залози виник у 8,1% дітей, прооперованих з приводу ХГ. Зазвичай його виявляли лише гістологічно. Це свідчить про діагностичні обмеження ультразвуку та ТАПБ у цьому контексті. Наявність лімфоїдної інфільтрації може бути важливою гістоморфологічною ознакою. Усі пацієнти мали сприятливий післяопераційний прогноз.
- 30 September 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 29-34
Open AccessПісляопераційно діагностовані карциноми щитоподібної залози при хворобі Грейвса у дітей
Хвороба Грейвса (ХГ) у дітей трапляється нечасто, уражаючи 1,5—6,5 осіб на 100 тис. населення зі збільшенням частоти в підлітковому віці. Захворюваність на рак щитоподібної залози (РЩЗ), який рідко спостерігається в педіатричній практиці, зростає. Поєднання ХГ і РЩЗ недостатньо висвітлено в літературі. Тому актуальним є вивчення перебігу та результатів хірургічного лікування при РЩЗ у дітей, прооперованих з приводу ХГ. Мета роботи — вивчити особливості перебігу карциноми щитоподібної залози, діагностованої після операції з приводу ХГ у дітей. Матеріали та методи. Проаналізовано 660 історій хвороби дітей (≤ 18 років), які перенесли операцію на щитоподібній залозі в 2013—2024 рр., із них 74 мали ХГ. У 6 (8,1%) дітей після операції діагностовано рак ЩЗ. Доопераційна діагностика передбачала дослідження функції щитоподібної залози, ультразвукове дослідження (УЗД) і тонкоголкову аспіраційну пункційну біопсію (ТАПБ) в окремих випадках, післяопераційне спостереження — УЗД і гормональний контроль кожні 6 міс. Результати. Більшість пацієнтів (82,4%) були підлітками (середній вік — близько 15 років). Серед пацієнтів переважали дівчата. Рак діагностований лише після операції, тобто не виявлений до операції за даними УЗД або ТАПБ. Усі 6 випадків раку були папілярними мікрокарциномами щитоподібної залози (< 10 мм, T1aN0М0). Лімфоїдна інфільтрація наявна в усіх випадках раку, навіть у навколишній тканині. Післяопераційні ускладнення мали минущий характер: у 20,0% — гіпопаратиреоз, у 9,1% — парез зворотного гортанного нерва. Тривале спостереження за дітьми з установленим раком щитоподібної залози на тлі ХГ не виявило рецидивів, у 3 із них — понад 5 років. Висновки. Рак щитоподібної залози виник у 8,1% дітей, прооперованих з приводу ХГ. Зазвичай його виявляли лише гістологічно. Це свідчить про діагностичні обмеження ультразвуку та ТАПБ у цьому контексті. Наявність лімфоїдної інфільтрації може бути важливою гістоморфологічною ознакою. Усі пацієнти мали сприятливий післяопераційний прогноз.
- Open Access
- 30 September 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 5-10
Власний досвід органозберігаючих операцій у дітей із приводу папілярного раку щитоподібної залози
Папілярний рак є найпоширенішим злоякісним новоутворенням щитоподібної залози. Захворюваність на диференційований рак щитоподібної залози у дітей зростає здебільшого через поліпшення діагностики та візуалізації, а не агресивності хвороби. Більшість досліджень зосереджувалися на захворюваності на папілярний рак щитоподібної залози (ПРЩЗ) у дітей, спричиненій радіаційним опроміненням після аварії на Чорнобильській АЕС. Традиційно в Україні переважала тотальна тиреоїдектомія(ТЕ) з лімфодисекцією, що супроводжувалося значною кількістю ускладнень. Мета роботи — дослідити результати органозберігаючих операцій при папілярному раку щитоподібної залози категорії низького ризику в дітей і визначити необхідні умови для їх виконання. Матеріали та методи. У дослідження було залучено 79 дітей віком 4—18 років, прооперовані у 2020—2025 рр., із них 66 виконано тотальну ТЕ, 13 — гемітиреоїдектомію (ГТЕ) за чіткими критеріями (pT1—2N0Mx, інтрамуральне розташування пухлини, відсутність метастазів). Оцінювали безрецидивну виживаність, частоту ускладнень (гіпокальціємія, парез гортані) та потребу в замісній гормональній терапії (ЗГТ). Результати. Рецидиви виявлено лише в 2 (3%) пацієнтів після ТЕ з категорією pT1—4N1a‑bMх. У групах pT1—2N0Mx після ТЕ та ГТЕ рецидивів не зафіксовано. Безрецидивна виживаність становила 96,97% після ТЕ й 100% після органозберігаючих втручань. Частота гіпокальціємії після ТЕ — 28,8%, після ГТЕ — 7,7%. Парез гортані зареєстровано в 16,7% пацієнтів лише після ТЕ. Більшість дітей після ГТЕ (70,7%) не потребували ЗГТ. Отримані результати свідчать про доцільність застосування органозберігаючих операцій у дітей із ПРЩЗ низького ризику. Вони дають змогу уникнути значної частини ускладнень, зберігаючи онкологічну безпечність. Відсутність рецидивів у пацієнтів із pT1—2N0Mx підтверджує ефективність обраної тактики. Порівняння з дорослими пацієнтами не виявило статистично значущої різниці за потребою в ЗГТ, що свідчить про збереження функції залишкової тканини щитоподібної залози в дітей. Висновки. Органозберігаючі операції є безпечними та ефективними для дітей із ПРЩЗ низького ризику. Вони знижують частоту ускладнень, зменшують потребу в ЗГТ та не впливають на онкологічні результати. Необхідно впровадити національні протоколи, що враховують сучасні міжнародні рекомендації та локальні особливості.
- 30 September 2025
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 5-10
Open AccessВласний досвід органозберігаючих операцій у дітей із приводу папілярного раку щитоподібної залози
Папілярний рак є найпоширенішим злоякісним новоутворенням щитоподібної залози. Захворюваність на диференційований рак щитоподібної залози у дітей зростає здебільшого через поліпшення діагностики та візуалізації, а не агресивності хвороби. Більшість досліджень зосереджувалися на захворюваності на папілярний рак щитоподібної залози (ПРЩЗ) у дітей, спричиненій радіаційним опроміненням після аварії на Чорнобильській АЕС. Традиційно в Україні переважала тотальна тиреоїдектомія(ТЕ) з лімфодисекцією, що супроводжувалося значною кількістю ускладнень. Мета роботи — дослідити результати органозберігаючих операцій при папілярному раку щитоподібної залози категорії низького ризику в дітей і визначити необхідні умови для їх виконання. Матеріали та методи. У дослідження було залучено 79 дітей віком 4—18 років, прооперовані у 2020—2025 рр., із них 66 виконано тотальну ТЕ, 13 — гемітиреоїдектомію (ГТЕ) за чіткими критеріями (pT1—2N0Mx, інтрамуральне розташування пухлини, відсутність метастазів). Оцінювали безрецидивну виживаність, частоту ускладнень (гіпокальціємія, парез гортані) та потребу в замісній гормональній терапії (ЗГТ). Результати. Рецидиви виявлено лише в 2 (3%) пацієнтів після ТЕ з категорією pT1—4N1a‑bMх. У групах pT1—2N0Mx після ТЕ та ГТЕ рецидивів не зафіксовано. Безрецидивна виживаність становила 96,97% після ТЕ й 100% після органозберігаючих втручань. Частота гіпокальціємії після ТЕ — 28,8%, після ГТЕ — 7,7%. Парез гортані зареєстровано в 16,7% пацієнтів лише після ТЕ. Більшість дітей після ГТЕ (70,7%) не потребували ЗГТ. Отримані результати свідчать про доцільність застосування органозберігаючих операцій у дітей із ПРЩЗ низького ризику. Вони дають змогу уникнути значної частини ускладнень, зберігаючи онкологічну безпечність. Відсутність рецидивів у пацієнтів із pT1—2N0Mx підтверджує ефективність обраної тактики. Порівняння з дорослими пацієнтами не виявило статистично значущої різниці за потребою в ЗГТ, що свідчить про збереження функції залишкової тканини щитоподібної залози в дітей. Висновки. Органозберігаючі операції є безпечними та ефективними для дітей із ПРЩЗ низького ризику. Вони знижують частоту ускладнень, зменшують потребу в ЗГТ та не впливають на онкологічні результати. Необхідно впровадити національні протоколи, що враховують сучасні міжнародні рекомендації та локальні особливості.
- Open Access
- 31 December 2024
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 4,p. 27-35
10 years of experience in providing surgical care to children with nodular and diffuse toxic goiter
Objective — to study the structure of thyroid diseases in children who required surgical treatment, analyze their gender and age distribution, and assess preoperative, intraoperative, and postoperative courses for thyroid nodules (TN) and diffuse toxic goiter (DTG). The study also aimed to evaluate the frequency of early and late complications, disease recurrences, and further treatment approaches. Materials and methods. This retrospective cohort study included 456 children (under 18 years of age) who underwent thyroidectomy at the Center between 2013—2022. According to the results of clinical and laboratory data and final pathohistological examination, all patients were divided into 3 groups: thyroid cancer (n=241), TN (n=151) and DTG (n=64). In the preoperative period, the duration of the disease, patients’ age, sex distribution, thyroid function, the results of instrumental examinations (thyroid ultrasound, FNAB with cytological assessment according to Bethesda) were investigated in patients with TN and DTG. In patients with TN and DTG, available for further postoperative follow up, the postoperative thyroid function, frequency of early and late complications and further treatment were studied. Results. Among all thyroid diseases that required surgical intervention, thyroid cancer (52.8%) and female gender (75%) prevailed. The mean age of the operated children was 14.4±2.5 years. TN were significantly more frequent in pubertal age group (p <0.05). The mean duration of the disease before surgery in case of TN was shorter than in DTG (p <0.001). Thyroidectomy was most often done in DTG, and hemithyroidectomy (HT) and/or HT + lymphadenectomy (LD) in case of TN. In 21.3% of patients with TN after HT/HT + LD, euthyroidism was acheived. In patients with DTG in the late postoperative period, persistent hypoparathyroidism was the only and most frequent complication (n=2, 12.5%). In contrast, in TN in the late postoperative period, 7 patients (10%) were diagnosed with a relapse of the disease, which occurred more often in younger children (13.0 [13.0; 14.0] years) compared to the group without relapse (p=0.01). Treatment of relapse included follow‑up in the majority of patients with TN (71.4%). Conclusions. Thyroid cancer predominated among thyroid diseases requiring surgical intervention. Persistent hypoparathyroidism was the only late complication in DTG cases. Considering the preservation of euthyroidism in 21.3% of patients with TN after HT/HT+LD, broader use of organ‑preserving surgeries should be considered, with further evaluation of postoperative hormone replacement therapy.
- 31 December 2024
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 4,p. 27-35
Open Access10 years of experience in providing surgical care to children with nodular and diffuse toxic goiter
Objective — to study the structure of thyroid diseases in children who required surgical treatment, analyze their gender and age distribution, and assess preoperative, intraoperative, and postoperative courses for thyroid nodules (TN) and diffuse toxic goiter (DTG). The study also aimed to evaluate the frequency of early and late complications, disease recurrences, and further treatment approaches. Materials and methods. This retrospective cohort study included 456 children (under 18 years of age) who underwent thyroidectomy at the Center between 2013—2022. According to the results of clinical and laboratory data and final pathohistological examination, all patients were divided into 3 groups: thyroid cancer (n=241), TN (n=151) and DTG (n=64). In the preoperative period, the duration of the disease, patients’ age, sex distribution, thyroid function, the results of instrumental examinations (thyroid ultrasound, FNAB with cytological assessment according to Bethesda) were investigated in patients with TN and DTG. In patients with TN and DTG, available for further postoperative follow up, the postoperative thyroid function, frequency of early and late complications and further treatment were studied. Results. Among all thyroid diseases that required surgical intervention, thyroid cancer (52.8%) and female gender (75%) prevailed. The mean age of the operated children was 14.4±2.5 years. TN were significantly more frequent in pubertal age group (p <0.05). The mean duration of the disease before surgery in case of TN was shorter than in DTG (p <0.001). Thyroidectomy was most often done in DTG, and hemithyroidectomy (HT) and/or HT + lymphadenectomy (LD) in case of TN. In 21.3% of patients with TN after HT/HT + LD, euthyroidism was acheived. In patients with DTG in the late postoperative period, persistent hypoparathyroidism was the only and most frequent complication (n=2, 12.5%). In contrast, in TN in the late postoperative period, 7 patients (10%) were diagnosed with a relapse of the disease, which occurred more often in younger children (13.0 [13.0; 14.0] years) compared to the group without relapse (p=0.01). Treatment of relapse included follow‑up in the majority of patients with TN (71.4%). Conclusions. Thyroid cancer predominated among thyroid diseases requiring surgical intervention. Persistent hypoparathyroidism was the only late complication in DTG cases. Considering the preservation of euthyroidism in 21.3% of patients with TN after HT/HT+LD, broader use of organ‑preserving surgeries should be considered, with further evaluation of postoperative hormone replacement therapy.
- Open Access
- 31 December 2024
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 4,p. 12-19
Possibilities of immunohistochemical markers HBME-1, TROP-2, Galectin-3 and Ki-67 to optimize the diagnosis of follicular carcinomas
In clinical practice, there is a diagnostic dilemma in the morphological examination in the verification of follicular carcinomas of the thyroid gland (FTC) and follicular adenoma (FA) among patients who were operated on for a nodular goiter with Bethesda III, IV and V cytological findings. Objective — To study the effectiveness of the use of immunohistochemical (IGH) markers HBME‑1, TROP‑2, Galectin‑3 and Ki‑67 in the diagnosis of FA and FTC on the histological material of patients who were operated on for nodular goiter with a cytological conclusion according to the Bethesda classification III, IV and V. Materials and methods. 124 patients operated on for follicular nodular neoplasms with a cytological conclusion according to Bethesda «Gray zone» were studied, as a result of the pathohistological examination, it was established: FTC — 26 (20.97%), FA — 98 (79.03%). IGH was performed using monoclonal antibodies against human HBME‑1, TROP‑2, Galectin‑3 and Ki‑67 («Bio SB», USA). Evaluation criteria were based on the intensity of staining (scale of 0 to 3) Results. TROP‑2 and Ki‑67 markers provide the highest overall diagnostic efficiency due to high specificity (93.9% and 96.9%, respectively). However, their sensitivity is extremely low (11.5% — Ki‑67, 0% — TROP‑2). That is, these tests have practically no diagnostic utility. From the point of view of detecting the disease, the test based on HBME‑1 is the most useful (sensitivity — 88.5%): only 3 cases out of 26 were missed, but it gives a lot of false positives: 74 out of 98. The test based on Galectin‑3 relatively accurately determines the absence of the disease — correctly identified 78 out of 98 such cases (specificity — 79.6%), but at the same time it is practically ineffective in finding the disease — 9 «triggers» out of 26 cases of FTC. If there is a simultaneous absence of the reaction of the HBME‑1 and Galectin‑3 markers, with a probability of approximately 0.9, it can be expected that the patient does not have FTC. On the other hand, with the maximum strength of the reaction, the probability of detecting FTC reaches 0.667. Conclusions. HBME‑1 (sensitivity 88.5%) turned out to be the most significant IGH marker in the differential diagnosis between FA and FTC. Markers TROP‑2 and Ki‑67 on the IGH study were practically not useful in the detection of FTC (sensitivity 0 and 11.5% respectively). The combined use of HBME‑1 and Galectin‑3 markers proved that the absence of an IGH reaction can be interpreted in favor of the presence of FA in the patient, and the simultaneous positive reaction of both markers is a warning regarding the diagnosis of FTC.
- 31 December 2024
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 4,p. 12-19
Open AccessPossibilities of immunohistochemical markers HBME-1, TROP-2, Galectin-3 and Ki-67 to optimize the diagnosis of follicular carcinomas
In clinical practice, there is a diagnostic dilemma in the morphological examination in the verification of follicular carcinomas of the thyroid gland (FTC) and follicular adenoma (FA) among patients who were operated on for a nodular goiter with Bethesda III, IV and V cytological findings. Objective — To study the effectiveness of the use of immunohistochemical (IGH) markers HBME‑1, TROP‑2, Galectin‑3 and Ki‑67 in the diagnosis of FA and FTC on the histological material of patients who were operated on for nodular goiter with a cytological conclusion according to the Bethesda classification III, IV and V. Materials and methods. 124 patients operated on for follicular nodular neoplasms with a cytological conclusion according to Bethesda «Gray zone» were studied, as a result of the pathohistological examination, it was established: FTC — 26 (20.97%), FA — 98 (79.03%). IGH was performed using monoclonal antibodies against human HBME‑1, TROP‑2, Galectin‑3 and Ki‑67 («Bio SB», USA). Evaluation criteria were based on the intensity of staining (scale of 0 to 3) Results. TROP‑2 and Ki‑67 markers provide the highest overall diagnostic efficiency due to high specificity (93.9% and 96.9%, respectively). However, their sensitivity is extremely low (11.5% — Ki‑67, 0% — TROP‑2). That is, these tests have practically no diagnostic utility. From the point of view of detecting the disease, the test based on HBME‑1 is the most useful (sensitivity — 88.5%): only 3 cases out of 26 were missed, but it gives a lot of false positives: 74 out of 98. The test based on Galectin‑3 relatively accurately determines the absence of the disease — correctly identified 78 out of 98 such cases (specificity — 79.6%), but at the same time it is practically ineffective in finding the disease — 9 «triggers» out of 26 cases of FTC. If there is a simultaneous absence of the reaction of the HBME‑1 and Galectin‑3 markers, with a probability of approximately 0.9, it can be expected that the patient does not have FTC. On the other hand, with the maximum strength of the reaction, the probability of detecting FTC reaches 0.667. Conclusions. HBME‑1 (sensitivity 88.5%) turned out to be the most significant IGH marker in the differential diagnosis between FA and FTC. Markers TROP‑2 and Ki‑67 on the IGH study were practically not useful in the detection of FTC (sensitivity 0 and 11.5% respectively). The combined use of HBME‑1 and Galectin‑3 markers proved that the absence of an IGH reaction can be interpreted in favor of the presence of FA in the patient, and the simultaneous positive reaction of both markers is a warning regarding the diagnosis of FTC.
- Open Access
- 30 October 2024
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 20 (6) , 447-451
Use of the immunohistochemical marker HBME-1 to optimize the diagnosis of follicular carcinomas
Background. In clinical practice, there are often patients with a diagnosis of benign follicular adenoma (FA) and follicular tumor with an uncertain malignant potential, whose diagnoses must be changed to malignant processes due to relapse or metastasis observed over time. The purpose of the study was to optimize the differential diagnosis of FA and follicular thyroid carcinoma (FTC) using the immunohistochemical (IHC) marker HBME-1 on the histological material of patients who were operated for nodular goiter with a cytological conclusion corresponding to the Bethesda categories III–V. Materials and methods. One hundred and twenty-four patients underwent surgery for follicular nodular neoplasms with a cytological conclusion according to Bethesda Gray zone and had a histological diagnosis of FTC in 23 cases (18.55 %) and FA in 101 cases (81.45 %). IHC analysis was performed using mouse monoclonal antibodies against human HBME-1 (Bio SB, USA). Evaluation criteria corresponded to the strength of staining (from 0 to 3). Results. According to the intensity of IHC staining, there was an increase in the diagnosis of FTC (p < 0.05): 0 — 0 %, 1 — 12.7 %, 2 — 25 %, 3 — 36.4 %. Histopathological findings were reexamined for FA that had the strongest staining reaction: in 3 (2.97 %) cases, the diagnosis was changed to FTC. Accordingly, the total number of detected FTC increased to 26 (20.96 %). These cases showed a good positive result regarding IHC study with HMBE-1 on FA preparations for a differential diagnosis between FA and FTC. Conclusions. HBME-1 can serve as an IHC marker for the differential diagnosis of FA and FTC in cases considered as FA, as after the study, the diagnosis was changed to FTC in 2.97 % of patients.
- 30 October 2024
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 20 (6) , 447-451
Open AccessUse of the immunohistochemical marker HBME-1 to optimize the diagnosis of follicular carcinomas
Background. In clinical practice, there are often patients with a diagnosis of benign follicular adenoma (FA) and follicular tumor with an uncertain malignant potential, whose diagnoses must be changed to malignant processes due to relapse or metastasis observed over time. The purpose of the study was to optimize the differential diagnosis of FA and follicular thyroid carcinoma (FTC) using the immunohistochemical (IHC) marker HBME-1 on the histological material of patients who were operated for nodular goiter with a cytological conclusion corresponding to the Bethesda categories III–V. Materials and methods. One hundred and twenty-four patients underwent surgery for follicular nodular neoplasms with a cytological conclusion according to Bethesda Gray zone and had a histological diagnosis of FTC in 23 cases (18.55 %) and FA in 101 cases (81.45 %). IHC analysis was performed using mouse monoclonal antibodies against human HBME-1 (Bio SB, USA). Evaluation criteria corresponded to the strength of staining (from 0 to 3). Results. According to the intensity of IHC staining, there was an increase in the diagnosis of FTC (p < 0.05): 0 — 0 %, 1 — 12.7 %, 2 — 25 %, 3 — 36.4 %. Histopathological findings were reexamined for FA that had the strongest staining reaction: in 3 (2.97 %) cases, the diagnosis was changed to FTC. Accordingly, the total number of detected FTC increased to 26 (20.96 %). These cases showed a good positive result regarding IHC study with HMBE-1 on FA preparations for a differential diagnosis between FA and FTC. Conclusions. HBME-1 can serve as an IHC marker for the differential diagnosis of FA and FTC in cases considered as FA, as after the study, the diagnosis was changed to FTC in 2.97 % of patients.
- Open Access
- 30 September 2023
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 5-11
Possibilities of immunocytochemical staining for HBME-1 expression in the «diagnostic search» of differentiated thyroid cancer. Own investigation
Objective — to investigate HBME-1 expression variants on cytological material classified as doubtful (III, IV, V), according to the Bethesda categories, to evaluate the value of the HBME-1 expression test on the corresponding histological material of nodular goiter, follicular tumor with an uncertain potential for malignancy for the differential diagnosis of thyroid carcinoma (ThC). Materials and methods. The analysis was performed on the data of 14 patients with thyroid nodular lesions and cytological Bethesda categories III, IV, and V (“gray zone“). The HBME-1 expression was determined by the results of immunocytochemical (ICC) and immunohistochemical (IHC) staining with the use of mouse monoclonal antibodies against human HBME-1 (1 : 500; cat № BSB 3459; «Bio SB» «Bioscince for the World» Santa Barbara USA). The HBME-1 expression grade was calculated as the sum of the score for staining intensity and cytoplasmic positive cells square, present in the IHC sample. HBME-1 positive result was considered with an IHC score >6 point. Results. From 14 investigated patients, five were defined as HBME-1 positive. According to the postoperative histological conclusion for the group of HBME-1 positive patients, thyroid carcinoma was diagnosed in four subjects, including three cases of papillary ThC and one follicular ThC; in one patient follicular tumor of uncertain malignant potential (FT-UMP) was reported. Importantly, immunocytochemical and immunohistochemical HBME-1 reactions in the specimens of these patients were of the same intensity. Among 9 HBME-1 preoperative negative patients, none had malignancy according to the final histological study. Nodular goiter was diagnosed in six patients, and tumor of uncertain malignant potential (FT-UMP) was reported for three subjects. Histological specimens of all 9 patients were HBME-1 negative as well. The obtained results demonstrated an increase in cancer detection rates with increasing Bethesda category. Application of statistical software for biomedical research МedCalc revealed that positive predictive value (PPV) of the HBME-1 expression test was 80% (95% confidence interval CI 38.4—96.3%), and diagnostic efficiency was 92.9% (CI 66.1—99.8%). These results suggest the great potential of the test, however, due to the limited observations, the confidence intervals are too wide. Conclusions. HBME-1 can be used as an immunocytochemical marker for the differentiation of benign and malignant thyroid nodules, its use will help to reduce the number of unnecessary surgical removals of benign tumors, which will improve the quality of life of patients and reduce the burden on medical services.
- 30 September 2023
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 5-11
Open AccessPossibilities of immunocytochemical staining for HBME-1 expression in the «diagnostic search» of differentiated thyroid cancer. Own investigation
Objective — to investigate HBME-1 expression variants on cytological material classified as doubtful (III, IV, V), according to the Bethesda categories, to evaluate the value of the HBME-1 expression test on the corresponding histological material of nodular goiter, follicular tumor with an uncertain potential for malignancy for the differential diagnosis of thyroid carcinoma (ThC). Materials and methods. The analysis was performed on the data of 14 patients with thyroid nodular lesions and cytological Bethesda categories III, IV, and V (“gray zone“). The HBME-1 expression was determined by the results of immunocytochemical (ICC) and immunohistochemical (IHC) staining with the use of mouse monoclonal antibodies against human HBME-1 (1 : 500; cat № BSB 3459; «Bio SB» «Bioscince for the World» Santa Barbara USA). The HBME-1 expression grade was calculated as the sum of the score for staining intensity and cytoplasmic positive cells square, present in the IHC sample. HBME-1 positive result was considered with an IHC score >6 point. Results. From 14 investigated patients, five were defined as HBME-1 positive. According to the postoperative histological conclusion for the group of HBME-1 positive patients, thyroid carcinoma was diagnosed in four subjects, including three cases of papillary ThC and one follicular ThC; in one patient follicular tumor of uncertain malignant potential (FT-UMP) was reported. Importantly, immunocytochemical and immunohistochemical HBME-1 reactions in the specimens of these patients were of the same intensity. Among 9 HBME-1 preoperative negative patients, none had malignancy according to the final histological study. Nodular goiter was diagnosed in six patients, and tumor of uncertain malignant potential (FT-UMP) was reported for three subjects. Histological specimens of all 9 patients were HBME-1 negative as well. The obtained results demonstrated an increase in cancer detection rates with increasing Bethesda category. Application of statistical software for biomedical research МedCalc revealed that positive predictive value (PPV) of the HBME-1 expression test was 80% (95% confidence interval CI 38.4—96.3%), and diagnostic efficiency was 92.9% (CI 66.1—99.8%). These results suggest the great potential of the test, however, due to the limited observations, the confidence intervals are too wide. Conclusions. HBME-1 can be used as an immunocytochemical marker for the differentiation of benign and malignant thyroid nodules, its use will help to reduce the number of unnecessary surgical removals of benign tumors, which will improve the quality of life of patients and reduce the burden on medical services.
- Open Access
- 30 March 2023
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 69-78
Papillary thyroid cancer in children. Clinical cases
Thyroid cancer (TC) is the most common endocrine tumor in pediatric patients. Papillary carcinoma accounts for the highest rate among differentiated TCs (80—90%). Papillary thyroid cancer in children is clinically different from this pathology in adults. In comparison with adults, papillary thyroid cancer in children is diagnosed at later stages and is associated with a more aggressive course of the disease. Despite the high frequency of metastases and recurrences of papillary thyroid cancer in children, the prognosis remains favorable. In Ukraine, 10 years after the accident at the Chernobyl nuclear power plant, the average incidence rates of papillary thyroid cancer among children of all ages gradually decreased, but since 2010—2011, a negative trend towards an increase in the number of new cases of pathology, especially children under 14 years of age, has been restored. Several studies suggest that the increase in the incidence of papillary thyroid cancer is only partially explained by the increase in the number of preventive examinations performed, as there is also an increase in the detection of large tumors and the diagnosis of advanced stages of the disease.Over the past 14 years, 759 children aged 3 to 18 from all regions of Ukraine were operated in the clinic of the Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine (Center). From them, based on the results of histopathological examinations, papillary thyroid cancer was diagnosed in 290 (38.2%) children (including 73.45% girls and 26.55% boys). In most cases, the disease was diagnosed during adolescence, except for isolated cases among children of primary school and preschool age. The paper presents two clinical cases.Annual preventive thyroid ultrasound investigation is required for early diagnosis of nodular goiter, including malignant thyroid tumors, especially in children with a burdened family history of these tumors. Any nodular goiter in children should be considered potentially malignant until its benign nature is proven by appropriate qualified investigations. To ensure proper and timely verification of malignant thyroid tumors in pediatric patients, to avoid unjustified (insufficient or excessive) surgical treatment of children with thyroid tumors, such patients should be referred to medical institutions with modern diagnostic capabilities and expert‑level surgical experience in the treatment of children with nodular goiter and malignant thyroid tumors.
- 30 March 2023
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 69-78
Open AccessPapillary thyroid cancer in children. Clinical cases
Thyroid cancer (TC) is the most common endocrine tumor in pediatric patients. Papillary carcinoma accounts for the highest rate among differentiated TCs (80—90%). Papillary thyroid cancer in children is clinically different from this pathology in adults. In comparison with adults, papillary thyroid cancer in children is diagnosed at later stages and is associated with a more aggressive course of the disease. Despite the high frequency of metastases and recurrences of papillary thyroid cancer in children, the prognosis remains favorable. In Ukraine, 10 years after the accident at the Chernobyl nuclear power plant, the average incidence rates of papillary thyroid cancer among children of all ages gradually decreased, but since 2010—2011, a negative trend towards an increase in the number of new cases of pathology, especially children under 14 years of age, has been restored. Several studies suggest that the increase in the incidence of papillary thyroid cancer is only partially explained by the increase in the number of preventive examinations performed, as there is also an increase in the detection of large tumors and the diagnosis of advanced stages of the disease.Over the past 14 years, 759 children aged 3 to 18 from all regions of Ukraine were operated in the clinic of the Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine (Center). From them, based on the results of histopathological examinations, papillary thyroid cancer was diagnosed in 290 (38.2%) children (including 73.45% girls and 26.55% boys). In most cases, the disease was diagnosed during adolescence, except for isolated cases among children of primary school and preschool age. The paper presents two clinical cases.Annual preventive thyroid ultrasound investigation is required for early diagnosis of nodular goiter, including malignant thyroid tumors, especially in children with a burdened family history of these tumors. Any nodular goiter in children should be considered potentially malignant until its benign nature is proven by appropriate qualified investigations. To ensure proper and timely verification of malignant thyroid tumors in pediatric patients, to avoid unjustified (insufficient or excessive) surgical treatment of children with thyroid tumors, such patients should be referred to medical institutions with modern diagnostic capabilities and expert‑level surgical experience in the treatment of children with nodular goiter and malignant thyroid tumors.
- Open Access
- 30 September 2022
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 7-12
Level of parathyroid hormone in the early postoperative period as a prognostic factor for persistent manifestations of clinical hypocalcemia
Objective — to determine the level of parathyroid hormone (PTH) in the early postoperative period in patients after the thyroid gland surgery, which enables to define the risk of persistent postoperative hypoparathyroidism with clinical manifestations of hypocalcemia. Materials and methods. The study involved 303 patients who were operated in the Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organ and Tissue due to various thyroid pathologies in the period of January, 2020 through June, 2021. The scope of the operation was thyroidectomy with/without lymph node dissection. The PTH level in blood serum was determined for all patients in the morning after the surgery (16 — 22 hours later). Clinical signs of hypocalcemia due to hypoparathyroidism (PTH level < 15 pg/ml) were revealed in 147 (48.5 %) subjects. Moving forward, such patients were examined for blood serum PTH levels after 3 months (first stage of examinations) and 6 months (second stage of examinations). Results. After 3 months, normalization of PTH levels and no clinical hypocalcemia manifestations were defined in 126 patients (85.7 %); 21 patients (14.3 %) had low PTH levels (< 15 pg/ml) with clinical manifestations of hypocalcemia. The use of ROC‑analysis to predict the normalization of PTH levels after 3 months revealed the cut‑off threshold 2.8 pg/ ml. After 6 months, normalization of PTH levels and no clinical hypocalcemia manifestations were defined in 136 (92.5 %) patients, whereas 11 (7.4 %) subjects demonstrated the reduced PTH levels and clinical manifestations of hypocalcemia. Results of ROC‑analysis prediction of the normalization of PTH levels after 6 months post‑surgery, the cut‑off threshold 1.6 pg/ml. Conclusions. Postoperative PTH levels > 2.8 pg/ml after 3 months after surgery and > 1.6 pg/ml after 6 months established to be a predictor of normalization serum PTH levels. A PTH level < 1.6 pg/ml can be considered a predictor of persistent hypoparathyroidism, and allows the physician to recognize patients with possible long‑term specific treatment.
- 30 September 2022
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 3,p. 7-12
Open AccessLevel of parathyroid hormone in the early postoperative period as a prognostic factor for persistent manifestations of clinical hypocalcemia
Objective — to determine the level of parathyroid hormone (PTH) in the early postoperative period in patients after the thyroid gland surgery, which enables to define the risk of persistent postoperative hypoparathyroidism with clinical manifestations of hypocalcemia. Materials and methods. The study involved 303 patients who were operated in the Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organ and Tissue due to various thyroid pathologies in the period of January, 2020 through June, 2021. The scope of the operation was thyroidectomy with/without lymph node dissection. The PTH level in blood serum was determined for all patients in the morning after the surgery (16 — 22 hours later). Clinical signs of hypocalcemia due to hypoparathyroidism (PTH level < 15 pg/ml) were revealed in 147 (48.5 %) subjects. Moving forward, such patients were examined for blood serum PTH levels after 3 months (first stage of examinations) and 6 months (second stage of examinations). Results. After 3 months, normalization of PTH levels and no clinical hypocalcemia manifestations were defined in 126 patients (85.7 %); 21 patients (14.3 %) had low PTH levels (< 15 pg/ml) with clinical manifestations of hypocalcemia. The use of ROC‑analysis to predict the normalization of PTH levels after 3 months revealed the cut‑off threshold 2.8 pg/ ml. After 6 months, normalization of PTH levels and no clinical hypocalcemia manifestations were defined in 136 (92.5 %) patients, whereas 11 (7.4 %) subjects demonstrated the reduced PTH levels and clinical manifestations of hypocalcemia. Results of ROC‑analysis prediction of the normalization of PTH levels after 6 months post‑surgery, the cut‑off threshold 1.6 pg/ml. Conclusions. Postoperative PTH levels > 2.8 pg/ml after 3 months after surgery and > 1.6 pg/ml after 6 months established to be a predictor of normalization serum PTH levels. A PTH level < 1.6 pg/ml can be considered a predictor of persistent hypoparathyroidism, and allows the physician to recognize patients with possible long‑term specific treatment.
- Open Access
- 31 March 2022
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 25-30
Predictive value of CD138, CD68, CD163 expression in the pathogenesis of the development of thyroid cancer against the background of metabolic disorders
Objective — to investigate the expression of CD138, CD68, CD163, involved in the pathogenesis of papillary thyroid cancer (PTC) against the background of metabolic disorders. Materials and methods. The analysis was performed on 36 selected medical histories of patients who were operated for PTC in the Surgical Department of the Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the MoH of Ukraine. Patients’ aged ranged 18 to 76 years, the mean age was 41.4 ± 13.8 years; women prevailed among patients — 32. According to the body mass index (BMI) patients were divided into two groups: group 1 (n = 14) with normal weight (BMI < 25 kg/m2), group 2 consisted of 22 overweight patients (BMI ≥ 25 kg/m2). All patients had autoimmune thyroiditis confirmed by laboratory and histological examination. Molecular genetic mutation BRAFV600E was detected in 20 (55.6 %). Immunohistochemical study of markers CD138, CD68, CD163 was performed according to the standard methods on histological material of tumors. Results. Among the studied immunohistochemical markers, CD68 was the most common — 72.2 % of cases, while CD138 and CD138 were found in 50 % and 55.6 %, respectively. In both studied groups, no statistically significant association was found between BMI and the presence of BRAFV600E (p > 0.05). In the immunohistochemical study of markers CD138, CD68 and CD163 no significant relationship between their expression and BMI was found (p > 0.05). Instead, we found a significant difference in the detection of the CD68 marker in patients of both groups (p < 0.01), while CD138 and CD163 did not show significant difference. The aggressiveness of the tumor process occurred in 25 % of patients. Patients in group 1 (with normal BMI) did not have significant differences in the aggressiveness in contrast to patients of the group 2 (21.4 % and 27.3 %, respectively). Conclusions. No increase of the expression of immunohistochemical markers CD138, CD68, CD163, involved in the pathogenesis of PTC, was established in overweight patients; there was no significant correlation between BMI and the presence of BRAFV600E, as well as the aggressiveness of the tumor process.
- 31 March 2022
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 1,p. 25-30
Open AccessPredictive value of CD138, CD68, CD163 expression in the pathogenesis of the development of thyroid cancer against the background of metabolic disorders
Objective — to investigate the expression of CD138, CD68, CD163, involved in the pathogenesis of papillary thyroid cancer (PTC) against the background of metabolic disorders. Materials and methods. The analysis was performed on 36 selected medical histories of patients who were operated for PTC in the Surgical Department of the Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the MoH of Ukraine. Patients’ aged ranged 18 to 76 years, the mean age was 41.4 ± 13.8 years; women prevailed among patients — 32. According to the body mass index (BMI) patients were divided into two groups: group 1 (n = 14) with normal weight (BMI < 25 kg/m2), group 2 consisted of 22 overweight patients (BMI ≥ 25 kg/m2). All patients had autoimmune thyroiditis confirmed by laboratory and histological examination. Molecular genetic mutation BRAFV600E was detected in 20 (55.6 %). Immunohistochemical study of markers CD138, CD68, CD163 was performed according to the standard methods on histological material of tumors. Results. Among the studied immunohistochemical markers, CD68 was the most common — 72.2 % of cases, while CD138 and CD138 were found in 50 % and 55.6 %, respectively. In both studied groups, no statistically significant association was found between BMI and the presence of BRAFV600E (p > 0.05). In the immunohistochemical study of markers CD138, CD68 and CD163 no significant relationship between their expression and BMI was found (p > 0.05). Instead, we found a significant difference in the detection of the CD68 marker in patients of both groups (p < 0.01), while CD138 and CD163 did not show significant difference. The aggressiveness of the tumor process occurred in 25 % of patients. Patients in group 1 (with normal BMI) did not have significant differences in the aggressiveness in contrast to patients of the group 2 (21.4 % and 27.3 %, respectively). Conclusions. No increase of the expression of immunohistochemical markers CD138, CD68, CD163, involved in the pathogenesis of PTC, was established in overweight patients; there was no significant correlation between BMI and the presence of BRAFV600E, as well as the aggressiveness of the tumor process.